<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Fri, 13 Mar 2026 22:40:46 -0400--><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel>
        <title>Rezolute, Inc. (RZLT) Press Releases</title>
        <link>https://ir.rezolutebio.com/news/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/_ccfa9d9a38d9c21c9cf5ba58fc58a234/rezolutebio/files/theme/images/logo-sm.png</url>
                <title>Rezolute, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Rezolute to Participate in the Citizens Life Sciences Conference]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., March  04, 2026  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia cau...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference</link>
                <pubDate>Wed, 04 Mar 26 07:00:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., Feb.  12, 2026  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caus...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update</link>
                <pubDate>Thu, 12 Feb 26 16:05:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caus...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/370/rezolute-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026</link>
                <pubDate>Wed, 04 Feb 26 07:00:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/370/rezolute-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism]]></title>
                <description><![CDATA[Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications
Company plans to meet with FDA to align on path forward for...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism</link>
                <pubDate>Wed, 07 Jan 26 07:00:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism]]></title>
                <description><![CDATA[

Study did not meet the primary or key secondary endpoint   45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm  Management to h...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism</link>
                <pubDate>Thu, 11 Dec 25 07:00:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., Nov.  10, 2025  (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia ca...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/367/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
                <pubDate>Mon, 10 Nov 25 17:30:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/367/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., Nov.  06, 2025  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caus...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/366/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update</link>
                <pubDate>Thu, 06 Nov 25 16:05:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/366/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute to Host Virtual Investor Event on Ersodetug Development Program]]></title>
                <description><![CDATA[

Webcast scheduled for Monday, November 10 at 12:00 pm EST

REDWOOD CITY, Calif., Nov.  05, 2025  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/365/rezolute-to-host-virtual-investor-event-on-ersodetug-development-program</link>
                <pubDate>Wed, 05 Nov 25 07:30:00 -0500</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/365/rezolute-to-host-virtual-investor-event-on-ersodetug-development-program</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute to Participate in Upcoming Investor Conferences]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., Oct.  15, 2025  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caus...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/364/rezolute-to-participate-in-upcoming-investor-conferences</link>
                <pubDate>Wed, 15 Oct 25 08:00:00 -0400</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/364/rezolute-to-participate-in-upcoming-investor-conferences</guid>
                                                                
            </item>
                    <item>
                <title><![CDATA[Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)]]></title>
                <description><![CDATA[

REDWOOD CITY, Calif., Oct.  09, 2025  (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia ca...]]></description>
                <link>https://ir.rezolutebio.com/news/detail/363/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
                <pubDate>Thu, 09 Oct 25 16:05:00 -0400</pubDate>
                <guid>https://ir.rezolutebio.com/news/detail/363/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
                                                                
            </item>
            </channel>
</rss>